Edinburgh Clinical Trials


Anaemia management with red Blood Cell transfusion to improve post-intensive care disability: a randomised controlled trial

Our trial will be the first to find out if an ICU patient’s health can be improved by treating their anaemia using blood transfusions from the time they leave the ICU. We will compare the current approach, which is to leave people more anaemic, with a more active approach of using blood transfusions to correct anaemia during the time they spend in hospital after leaving ICU. Patients will be randomly split into two groups and the allocated approach will be used from the time they leave ICU until they are discharged from hospital. We will measure the effect that treating anaemia with blood transfusions has on important patient outcomes such as quality of life, the ability to carry out daily tasks, symptoms of fatigue, and patients’ physical ability. Our trial will also explore which patients benefit most from blood transfusions and those who gain no benefit. We aim to establish which anaemic patients to treat with blood transfusions after ICU to help their recovery.



Chief Investigator: Professor Timothy Walsh

Number and location of participating sites / geographical scope (by region/ country): UK – 15 sites


Funder: JP Moulton Foundation Trust

Start and End date

Of grant award:  1 Nov 2019 - 31 August 2025

Of recruitment: Grant start date: September 2020

Current Status: Recruitment open in Edinburgh, set-up of other sites in Spring 2022



Study Protocol:


Example Patient Information Sheet:


ABC Post ICU frequently asked questions:


ABC Post ICU Rationale for Clinicians

Video: ABC trial Prof Tim Walsh
ABC trial Prof Tim Walsh


ABC Post ICU Autumn Relaunch 25th October 2023

Video: ABC Post ICU Autumn Relaunch 25th October 2023
ABC Post ICU Autumn Relaunch Meeting 2023


Co-enrolment between ABC Post ICU and the following CTIMP studies has been agreed: A2B, ABC Sepsis, ADD-Aspirin, MARCH, MOSAICC, SWIFT, SNAP-IT, VARICiSS

Co-enrolment between ABC Post ICU and the following non-CTIMP studies has been agreed: A prospective, single arm, multiple-centre study of the ENSEAL X1 curved jaw tissue selar and generator G11 in thoracic, urologic and ear nose and throat procedures, Adapt Sepsis, AFAR, , Autoflow, BIGPAK2 (only where patients are at least 72 hours post-surgery), Biomarkers associated with Postoperative Cognitive Dysfunction, CONDUCT ICU, GI DAMPS, Inference, iRehab, PREFIBRILLATE, PQIP, Scottish Colorectal Cancer Genetic Susceptibility Study 3 (SOCCS3), SR1418 SSCAMP, T4P, UK-ROX, VITAL

Co-enrolment between ABC Post ICU and the following observational/sampling studies has been agree: ARDS-Neut (participants in both PHIND & ARDS-Neut can also be co-enrolled), A-STOP, GenOMMIC, KRAKIL, PHIND


Sponsor: The University of Edinburgh and Lothian Health Board, ACCORD (ref: AC18022), The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ.  http://accord.scot/

Chief Investigator: Professor Timothy Walsh Timothy.Walsh@ed.ac.uk

Trial manager:  Alix Macdonald, contact the trial team on: ABC.Trial@ed.ac.uk


ECTU Involvement: Trial management /Statistics/ Database and randomisation service.